Clinical Trials

Sale

Macular Degeneration Drug Pipeline Analysis

Macular Degeneration Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Anti-VEGF (Vascular Endothelial Growth Factor) Agents, Anti-Inflammatory Agents (Corticosteroids), Complement Inhibitors; Product Type; By Treatment Type; Key Players

A study conducted in 2022 revealed that around 19.83 million Americans were affected by some form of age-related macular degeneration (AMD). Out of these, around 1.49 million people were affected by late-stage AMD.

 

The prevalence of developing the condition increases with age. It rises from 2% (for people aged 40 to 44 years) to 46.6% (for people aged above 85). As the global geriatric population is growing, the demand for high-efficacy macular degeneration drugs is on the rise. This has prompted major healthcare institutions to develop new drugs, resulting in an increased number of drugs in the pipeline.

 

Key Takeaways

  • Major companies involved in the macular degeneration drugs market include CHABiotech CO., Ltd., F. Hoffmann-La Roche AG, GSK Plc., Allegro Ophthalmics, LLC, Bayer AG, IVERIC bio, Inc., Allergan Inc., and others.
  • Leading drugs currently under the drug pipeline include GT005, CT1812, Ixo-vec and 4D-150 among others.
  • Regulatory authorities like the United States FDA and EMA play a vital role in the drug pipeline for macular degeneration as they offer breakthrough designations and fast-track approvals for accelerating access to new and effective treatment alternatives to patients.

 

Report Coverage

The Macular Degeneration Drug Pipeline Report by Expert Market Research gives comprehensive insights into macular degeneration drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on macular degeneration.

 

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to macular degeneration are covered.

 

Macular Degeneration Drug Pipeline Outlook

Age-related macular degeneration (AMD)  is a condition which damages a part of the retina (macula), leading to loss of central vision. It is commonly divided into two categories, namely, dry AMD and wet AMD. Dry age-related macular degeneration involves thinning of the macula with age and formation of drusen (small protein clumps). It is more common as compared to wet AMD. The American Academy of Ophthalmology reports that 8 out of 10 people are affected by dry AMD. Although less common, wet AMD is considered to be more serious as vision loss is faster in comparison to dry AMD. It involves the growth of new and abnormal blood vessels under the retina. These blood vessels may leak and scar the macula significantly.

 

AMD treatment involves the use of anti-VEGF therapies, which work by inhibiting abnormal vessel growth and decreasing the chance of fluid leakage. Photodynamic therapy and laser photocoagulation can also be used based on patient profiles. In 2023, two new drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) received the U.S. FDA’s approval for geographic atrophy (a late stage of dry AMD) treatment. These intravenous drugs slowed disease progression by about 14% to 20%.

 

For years, patients have been limited to using AREDS2 vitamins for treating intermediate stages of dry AMD. However, the approval of new drugs elevates hope for both patients and healthcare professionals to manage the condition more efficiently.

 

Macular Degeneration – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of macular degeneration drugs based on various segmentations such as:

 

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

 

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

 

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

 

  • Anti-VEGF (Vascular Endothelial Growth Factor) Agents
  • Anti-Inflammatory Agents
  • Complement Inhibitors

 

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

 

  • Oral
  • Parenteral
  • Others

 

Macular Degeneration – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials conducted, with over 550 drugs in the pipeline.

 

Macular Degeneration – Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under macular degeneration pipeline analysis include anti-VEGF (vascular endothelial growth factor) agents, anti-inflammatory agents (corticosteroids), complement inhibitors and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials. According to EMR analysis, gene therapy, stem cell therapy and other photodynamic therapies are under investigation and likely to impact the drug class landscape significantly in coming years.

 

Macular Degeneration Clinical Trials Assessment – Competitive Dynamics

The EMR report for the macular degeneration drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in macular degeneration clinical trials:

 

  • CHABiotech CO., Ltd
  • F. Hoffmann-La Roche AG
  • GSK Plc.
  • Allegro Ophthalmics, LLC
  • Bayer AG
  • IVERIC Bio, Inc.
  • Allergan Inc.
  • Others

 

Macular Degeneration – Pipeline Drugs Profile

GT005

This  investigational gene therapy is currently under phase 2 clinical trials of a program initiated by The Department of Ophthalmology at Columbia University Irving Medical Center. It acts on the complement factor I (CFI) protein that inhibits the immune system from attacking the retina cells. This intravenous drug intended to treat geographic atrophy secondary to dry age-related macular degeneration has also received Fast-Track Designation from the United States FDA.

 

Ixo-vec

Developed by Adverum  Biotechnologies Inc., this drug showed efficacy in over 90% of the subjects in the LUNA Phase 2 trial. This trial involves 60 patients with wet AMD and is divided across two dose cohorts 2E11 and 6E10 vg/eye. Both doses involved showed visual as well as anatomic outcomes, signifying its efficacy.

 

4D-150

4D  Molecular Therapeutics’ wet AMD drug candidate 4D-150 showed positive outcomes in Phase 2 PRISM clinical trial. This trial evaluated the safety, durability, and suitability of the drug. The company aims to present the drug for Phase 3 and apply for FDA RMAT and EMA PRIME designations as well.

 

CT-1812

Sponsored by Cognition Therapeutics, this drug is under evaluation to treat late-stage dry AMD. CT-1812 is a small-molecule oral medication that has the potential to cross the blood-retinal barrier and reach the back of the retina without injection intervention. The drug will be evaluated on 246 patients as a part of the Phase 2 MAGNIFY study.

 

Reasons To Buy This Report

The Macular Degeneration Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for macular degeneration. It provides the necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.

 

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
Route of Administration
  • Oral
  • Parenteral
  • Others
Drug Classes
  • Anti-VEGF (Vascular Endothelial Growth Factor) Agents
  • Anti-Inflammatory Agents
  • Complement Inhibitors
Leading Sponsors Covered
  • CHABiotech CO., Ltd 
  • F. Hoffmann-La Roche AG 
  • GSK Plc. 
  • Allegro Ophthalmics, LLC 
  • Bayer AG 
  • IVERIC Bio, Inc. 
  • Allergan Inc. 
  • Others
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

 

Key Questions Answered in the Macular Degeneration – Pipeline Assessment Report

  • What is the current landscape of macular degeneration pipeline drugs?
  • How many companies are developing macular degeneration drugs?
  • How many phase III and phase IV drugs are currently present in macular degeneration pipeline drugs?
  • Which companies/institutions are leading the macular degeneration drug development?
  • What is the efficacy and safety profile of macular degeneration pipeline drugs?
  • What are the opportunities and challenges present in the macular degeneration drug pipeline landscape?
  • Which company is conducting major trials for macular degeneration drugs?
  • What are the geographies covered for clinical trials in macular degeneration?
  • What are emerging trends in macular degeneration clinical trials?

 

Related Reports

Age-Related Macular Degeneration Market

Neovascular Age-Related Macular Degeneration Market

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Introduction
    1.2    Objectives of the Study
    1.3    Research Methodology and Assumptions
2    Executive Summary
3    Overview  of Macular Degeneration

    3.1    Signs and Symptoms
    3.2    Causes
    3.3    Risk Factors
    3.4    Types of Macular Degeneration
    3.5    Diagnosis
    3.6    Treatment
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Macular Degeneration: Epidemiology Snapshot
    5.1    Macular Degeneration Incidence by Key Markets
    5.2    Macular Degeneration– Patients Seeking Treatment in Key Markets
6    Macular Degeneration: Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
7    Macular Degeneration: Key Facts Covered
    7.1    Top Countries Contributing to Clinical Trials in Asia-Pacific
    7.2    Top Countries Contributing to Clinical Trials in Europe
    7.3    Top Countries Contributing to Clinical Trials in North America
    7.4    Top Countries Contributing to Clinical Trials in Other Regions
8    Macular Degeneration, Drug Pipeline Assessment
    8.1    Assessment by Treatment Type
    8.2    Assessment by Route of Administration
    8.3    Assessment by Drug Class
9    EMR  Drug Pipeline Comparative Analysis
    9.1    List of Macular Degeneration Pipeline Drugs
        9.1.1    By Company
        9.1.2    By Phase
        9.1.3    By Indication
        9.1.4    By Trial Status
        9.1.5    By Funder Type
    9.2    EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs) 
10    Macular Degeneration Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs) 
    10.1    Comparative Analysis for Late-Stage Drugs
        10.1.1    Study Type
        10.1.2    Recruitment Status
        10.1.3    Company
        10.1.4    Funder Type
    10.2    Product Level Analysis*
        10.2.1    Anecortave Acetate
            10.2.1.1    Product Description 
            10.2.1.2    Trial ID
            10.2.1.3    Sponsor Name
            10.2.1.4    Study Type
            10.2.1.5    Drug Class
            10.2.1.6    Eligibility Criteria
            10.2.1.7    Study Record Dates
                10.2.1.7.1    First Submitted
                10.2.1.7.2    First Posted
                10.2.1.7.3    Last Update Posted
                10.2.1.7.4    Last Verified
            10.2.1.8    Indication
            10.2.1.9    Study Design
            10.2.1.10    Recruitment Status
            10.2.1.11    Enrollment (Estimated)
            10.2.1.12    Location Countries
            10.2.1.13    Recent Results
        10.2.2    Ranibizumab
        10.2.3    Aflibercept
        10.2.4    Other Drug
11    Macular Degeneration Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs) 
    11.1    Comparative Analysis for Mid-Stage Drugs
        11.1.1    Study Type
        11.1.2    Recruitment Status
        11.1.3    Company
        11.1.4    Funder Type
    11.2    Product Level Analysis*
        11.2.1    MA09-hRPE
            11.2.1.1    Product Description 
            11.2.1.2    Trial ID
            11.2.1.3    Sponsor Name
            11.2.1.4    Study Type
            11.2.1.5    Drug Class
            11.2.1.6    Eligibility Criteria
            11.2.1.7    Study Record Dates
                11.2.1.7.1    First Submitted
                11.2.1.7.2    First Posted
                11.2.1.7.3    Last Update Posted
                11.2.1.7.4    Last Verified
            11.2.1.8    Indication
            11.2.1.9    Study Design
            11.2.1.10    Recruitment Status
            11.2.1.11    Enrollment (Estimated)
            11.2.1.12    Location Countries
            11.2.1.13    Recent Results
        11.2.2    Anecortave Acetate
        11.2.3    Avacincaptad Pegol
        11.2.4    Other Drugs
12    Macular Degeneration Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs) 
    12.1    Comparative Analysis for Early-Stage Drugs
        12.1.1    Study Type
        12.1.2    Recruitment Status
        12.1.3    Company
        12.1.4    Funder Type
    12.2    Product Level Analysis*
        12.2.1    ALG 1001
            12.2.1.1    Product Description 
            12.2.1.2    Trial ID
            12.2.1.3    Sponsor Name
            12.2.1.4    Study Type
            12.2.1.5    Drug Class
            12.2.1.6    Eligibility Criteria
            12.2.1.7    Study Record Dates
                12.2.1.7.1    First Submitted
                12.2.1.7.2    First Posted
                12.2.1.7.3    Last Update Posted
                12.2.1.7.4    Last Verified
            12.2.1.8    Indication
            12.2.1.9    Study Design
            12.2.1.10    Recruitment Status
            12.2.1.11    Enrollment (Estimated)
            12.2.1.12    Location Countries
        12.2.2    AdGVPEDF.11D
        12.2.3    BI 754132
        12.2.4    Other Drugs
13    Macular Degeneration Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs) 
    13.1    Comparative Analysis for Preclinical and Discovery Stage Drugs
        13.1.1    Study Type
        13.1.2    Recruitment Status
        13.1.3    Company
        13.1.4    Funder Type
    13.2    Product Level Analysis*
        13.2.1        HG202
            13.2.1.1    Product Description 
            13.2.1.2    Trial ID
            13.2.1.3    Sponsor Name
            13.2.1.4    Study Type
            13.2.1.5    Drug Class
            13.2.1.6    Eligibility Criteria
            13.2.1.7    Study Record Dates
                13.2.1.7.1    First Submitted
                13.2.1.7.2    First Posted
                13.2.1.7.3    Last Update Posted
                13.2.1.7.4    Last Verified
            13.2.1.8    Indication
            13.2.1.9    Study Design
            13.2.1.10    Recruitment Status
            13.2.1.11    Enrollment (Estimated)
            13.2.1.12    Location Countries
        13.2.2    BD311
        13.2.3    MB-102
        13.2.4    Other Drugs
14    Macular Degeneration, Key Drug Pipeline Companies
    14.1    CHABiotech CO., Ltd
        14.1.1    Company Snapshot
        14.1.2    Pipeline Product Portfolio
        14.1.3    Financial Analysis
        14.1.4    Recent News and Developments
    14.2    F. Hoffmann-La Roche AG
        14.2.1    Company Snapshot
        14.2.2    Pipeline Product Portfolio
        14.2.3    Financial Analysis
        14.2.4    Recent News and Developments
    14.3    GSK Plc.
        14.3.1    Company Snapshot
        14.3.2    Pipeline Product Portfolio
        14.3.3    Financial Analysis
        14.3.4    Recent News and Developments
    14.4    Allegro Ophthalmics, LLC
        14.4.1    Company Snapshot
        14.4.2    Pipeline Product Portfolio
        14.4.3    Financial Analysis
        14.4.4    Recent News and Developments
    14.5    Bayer AG
        14.5.1    Company Snapshot
        14.5.2    Pipeline Product Portfolio
        14.5.3    Financial Analysis
        14.5.4    Recent News and Developments
    14.6    IVERIC bio, Inc.
        14.6.1    Company Snapshot
        14.6.2    Pipeline Product Portfolio
        14.6.3    Financial Analysis
        14.6.4    Recent News and Developments
    14.7    Allergan Inc.
        14.7.1    Company Snapshot
        14.7.2    Pipeline Product Portfolio
        14.7.3    Financial Analysis
        14.7.4    Recent News and Developments
15    Regulatory Framework for Drug Approval, By Region
16    Terminated or Suspended Pipeline Products

 

*Complete list of drugs covered will be provided in the report.

 

The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.

Purchase Full Report

Mini Report

$ 2639     $2399
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 4399     $3999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 5829     $5299
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 6929     $6299
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER